Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia
- Year invested 2017
- Investment Stage Growth
- Board Members
- Sectors
- Investment Status Current
- Website trevitherapeutics.com/
- Company Status IPO/Public (NASDAQ: TRVI)